Synaptogenix (NASDAQ:SNPX) Shares Scheduled to Reverse Split on Friday, April 5th

Synaptogenix, Inc. (NASDAQ:SNPX)’s stock is going to reverse split on the morning of Friday, April 5th. The 1-25 reverse split was announced on Friday, April 5th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, April 5th.

Synaptogenix Stock Performance

NASDAQ SNPX remained flat at $0.18 on Wednesday. The company had a trading volume of 1,715,827 shares, compared to its average volume of 794,238. The company has a 50 day moving average of $0.19 and a 200 day moving average of $0.25. The company has a market capitalization of $3.67 million, a PE ratio of -0.17 and a beta of 1.33. Synaptogenix has a fifty-two week low of $0.14 and a fifty-two week high of $1.88.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Synaptogenix by 2.6% during the 3rd quarter. Vanguard Group Inc. now owns 222,495 shares of the company’s stock worth $1,491,000 after acquiring an additional 5,659 shares during the period. Renaissance Technologies LLC acquired a new position in Synaptogenix in the 2nd quarter valued at $83,000. Finally, Prelude Capital Management LLC raised its holdings in shares of Synaptogenix by 13.9% during the 2nd quarter. Prelude Capital Management LLC now owns 14,364 shares of the company’s stock worth $75,000 after buying an additional 1,750 shares in the last quarter. 10.34% of the stock is currently owned by institutional investors.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.